Parthenolide Inhibits the Proliferation and Induces the Apoptosis of Human Uveal Melanoma Cells

Overview

Journal Int J Ophthalmol

Specialty Ophthalmology

Date 2019 Oct 23

PMID 31637187

Citations 8

Authors

Song-Tian Che

Li Bie

Xu Li

Hui Qi

Peng Yu

Ling Zuo

Affiliations

Soon will be listed here.

Abstract

Aim: To explore the effect of parthenolide (PTL) on human uveal melanoma (UM) cells (C918 and SP6.5 cells) and its molecular mechanism.

Methods: Carboxyfluorescein succinimidyl amino ester (CFSE) assays and cell counting kit-8 (CCK-8) were performed to detect the cell viability. Flow cytometry was used to analyze cell cycle and apoptosis. Quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot assays were performed to measure proliferation-related and apoptosis-related factors.

Results: Firstly, PTL decreased the viability of C918 and SP6.5 cells in a dose-dependent manner, and the effect of PTL on C918 cells was stronger than on SP6.5; however, it did not affect normal cells. Secondly, PTL increased the proportion of cell number at cell cycle G1 phase in C918 cells, and decreased the proportion of cell number at S phase, but the proportion did not change at G2 phase. In addition, PTL induced the apoptosis of C918 cells, and decreased the expressions of Cyclin D1, B-cell lymphoma-2 (Bcl-2) and B-cell lymphoma-extra large (Bcl-XL). Also, PTL increased Cyclin inhibition protein 1 (P21), Bcl-2-associated X protein (Bax), Cysteinyl aspartate specific proteinas-3 (Caspase-3) and Caspase-9 expression. However, the expression of Caspase-8 was not changed.

Conclusion: PTL inhibites proliferation and induces apoptosis in UM cells by arresting G1 phase and regulating mitochondrial pathway, however, it does not affect normal cells.

Citing Articles

Natural Products and Altered Metabolism in Cancer: Therapeutic Targets and Mechanisms of Action.

Talib W, Baban M, Bulbul M, Al-Zaidaneen E, Allan A, Al-Rousan E Int J Mol Sci. 2024; 25(17).

PMID: 39273552 PMC: 11394730. DOI: 10.3390/ijms25179593.

Combination Anticancer Therapies Using Selected Phytochemicals.

Talib W, Awajan D, Hamed R, Azzam A, Mahmod A, Al-Yasari I Molecules. 2022; 27(17).

PMID: 36080219 PMC: 9458090. DOI: 10.3390/molecules27175452.

Plants as a Source of Anticancer Agents: From Bench to Bedside.

Talib W, Daoud S, Mahmod A, Hamed R, Awajan D, Abuarab S Molecules. 2022; 27(15).

PMID: 35956766 PMC: 9369847. DOI: 10.3390/molecules27154818.

The Emerging Potential of Parthenolide Nanoformulations in Tumor Therapy.

An T, Yin H, Lu Y, Liu F Drug Des Devel Ther. 2022; 16:1255-1272.

PMID: 35517982 PMC: 9063801. DOI: 10.2147/DDDT.S355059.

Diabetes and Cancer: Metabolic Association, Therapeutic Challenges, and the Role of Natural Products.

Talib W, Mahmod A, Abuarab S, Hasen E, Munaim A, Haif S Molecules. 2021; 26(8).

PMID: 33920079 PMC: 8070467. DOI: 10.3390/molecules26082179.

References

Li H, Lv B, Kong L, Xia J, Zhu M, Hu L . Nova1 mediates resistance of rat pheochromocytoma cells to hypoxia-induced apoptosis via the Bax/Bcl-2/caspase-3 pathway. Int J Mol Med. 2017; 40(4):1125-1133. PMC: 5593465. DOI: 10.3892/ijmm.2017.3089. View

Sun J, Zhang C, Bao Y, Wu Y, Chen Z, Yu C . Parthenolide-induced apoptosis, autophagy and suppression of proliferation in HepG2 cells. Asian Pac J Cancer Prev. 2014; 15(12):4897-902. DOI: 10.7314/apjcp.2014.15.12.4897. View

Jung Y, Qian Y, Chen X . Examination of the expanding pathways for the regulation of p21 expression and activity. Cell Signal. 2010; 22(7):1003-12. PMC: 2860671. DOI: 10.1016/j.cellsig.2010.01.013. View

Schwarz D, Bloom D, Castro R, Pagan O, Jimenez-Rivera C . Parthenolide Blocks Cocaine's Effect on Spontaneous Firing Activity of Dopaminergic Neurons in the Ventral Tegmental Area. Curr Neuropharmacol. 2011; 9(1):17-20. PMC: 3137176. DOI: 10.2174/157015911795017010. View

Yun B, Lee M, Kim J, Kim I, Yu G, Kim D . Enhancement of parthenolide-induced apoptosis by a PKC-alpha inhibition through heme oxygenase-1 blockage in cholangiocarcinoma cells. Exp Mol Med. 2010; 42(11):787-97. PMC: 2992858. DOI: 10.3858/emm.2010.42.11.082. View

Kemeny-Beke A, Berenyi E, Facsko A, Damjanovich J, Horvath A, Bodnar A . Antiproliferative effect of 4-thiouridylate on OCM-1 uveal melanoma cells. Eur J Ophthalmol. 2006; 16(5):680-5. View

Wyrebska A, Gach K, Szemraj J, Szewczyk K, Hrabec E, Koszuk J . Comparison of anti-invasive activity of parthenolide and 3-isopropyl-2-methyl-4-methyleneisoxazolidin-5-one (MZ-6)--a new compound with α-methylene-γ-lactone motif--on two breast cancer cell lines. Chem Biol Drug Des. 2011; 79(1):112-20. DOI: 10.1111/j.1747-0285.2011.01257.x. View

Sabbagh L, Kaech S, Bourbonniere M, Woo M, Cohen L, Haddad E . The selective increase in caspase-3 expression in effector but not memory T cells allows susceptibility to apoptosis. J Immunol. 2004; 173(9):5425-33. DOI: 10.4049/jimmunol.173.9.5425. View

Shanmugam R, Kusumanchi P, Cheng L, Crooks P, Neelakantan S, Matthews W . A water-soluble parthenolide analogue suppresses in vivo prostate cancer growth by targeting NFkappaB and generating reactive oxygen species. Prostate. 2010; 70(10):1074-86. DOI: 10.1002/pros.21141. View

10.

Chen M, Yang P, Ye Y, Hu D, Chen M . Arsenic trioxide induces apoptosis in uveal melanoma cells through the mitochondrial pathway. Am J Chin Med. 2010; 38(6):1131-42. DOI: 10.1142/S0192415X10008524. View

11.

Czyz M, Lesiak-Mieczkowska K, Koprowska K, Szulawska-Mroczek A, Wozniak M . Cell context-dependent activities of parthenolide in primary and metastatic melanoma cells. Br J Pharmacol. 2010; 160(5):1144-57. PMC: 2936024. DOI: 10.1111/j.1476-5381.2010.00749.x. View

12.

Li H, Lu H, Lv M, Wang Q, Sun Y . Parthenolide facilitates apoptosis and reverses drug-resistance of human gastric carcinoma cells by inhibiting the STAT3 signaling pathway. Oncol Lett. 2018; 15(3):3572-3579. PMC: 5796286. DOI: 10.3892/ol.2018.7739. View

13.

Hu D, Yu G, McCormick S, Schneider S, Finger P . Population-based incidence of uveal melanoma in various races and ethnic groups. Am J Ophthalmol. 2005; 140(4):612-7. DOI: 10.1016/j.ajo.2005.05.034. View

14.

Augsburger J, Correa Z, Shaikh A . Effectiveness of treatments for metastatic uveal melanoma. Am J Ophthalmol. 2009; 148(1):119-27. DOI: 10.1016/j.ajo.2009.01.023. View

15.

Li C, Guo S, Shi T . Culture supernatants of breast cancer cell line MDA-MB-231 treated with parthenolide inhibit the proliferation, migration, and lumen formation capacity of human umbilical vein endothelial cells. Chin Med J (Engl). 2012; 125(12):2195-9. View

16.

. Local Recurrence Significantly Increases the Risk of Metastatic Uveal Melanoma. Ophthalmology. 2015; 123(1):86-91. DOI: 10.1016/j.ophtha.2015.09.014. View

17.

Lane A, Kim I, Gragoudas E . Survival Rates in Patients After Treatment for Metastasis From Uveal Melanoma. JAMA Ophthalmol. 2018; 136(9):981-986. PMC: 6142974. DOI: 10.1001/jamaophthalmol.2018.2466. View

18.

Kaliki S, Shields C . Uveal melanoma: relatively rare but deadly cancer. Eye (Lond). 2016; 31(2):241-257. PMC: 5306463. DOI: 10.1038/eye.2016.275. View

19.

Wang Y, Yang X, Wei W, Xu X . Role of microRNA-21 in uveal melanoma cell invasion and metastasis by regulating p53 and its downstream protein. Int J Ophthalmol. 2018; 11(8):1258-1268. PMC: 6090126. DOI: 10.18240/ijo.2018.08.03. View

20.

Damato B . Detection of uveal melanoma by optometrists in the United Kingdom. Ophthalmic Physiol Opt. 2001; 21(4):268-71. DOI: 10.1046/j.1475-1313.2001.00595.x. View